5 Jan
2021

Generic drug pathway could be “decimated” by recent CAFC judgment

The outcome of Teva’s request for en banc review of a recent Federal Circuit decision is pivotal for patent strategies relating to generics with carve-out labels, prominent academics argue.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth